CVGBM
Phase 1- Indications
- Glioblastoma
Company intelligence / Profile preview
CureVac
Tübingen, Baden-Württemberg, Germanycurevac.com ↗
- Ownership
- Public · CVAC
- Employees
- ~700
- Development stage
- Phase 2
01
Overview
CureVac's COVID-19 vaccine candidate (CVnCoV) showed inadequate results in Phase III trials with only 47% efficacy in 2021. The company abandoned further development of CVnCoV and shifted focus to collaborating with GSK to develop improved mRNA vaccine technology. In 2024, they began Phase I/II clinical trials for an H5N1 avian influenza vaccine candidate.
- Therapeutic areas
- OphthalmologyOncologyInfectious Diseases
- Modalities
- mRNA-based therapeuticsmRNA vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
GSKBoehringer IngelheimSanofi PasteurJohnson & JohnsonGenmabBill & Melinda Gates FoundationEli Lilly and CompanyCoalition for Epidemic Preparedness Innovations (CEPI)International AIDS Vaccine Initiative
Beyond the preview
Go deeper on CureVac.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CureVac.